Abstract
The tumour microenvironment (TME) surrounding tumour cells is a highly dynamic and heterogeneous composition of immune cells, fibroblasts, precursor cells, endothelial cells, signalling molecules and extracellular matrix (ECM) components. Due to the heterogeneity and the constant crosstalk between the TME and the tumour cells, the components of the TME are important prognostic parameters in cancer and determine the response to novel immunotherapies. To improve the characterization of the TME, novel non-invasive imaging paradigms targeting the complexity of the TME are urgently needed.
The characterization of the TME by molecular imaging will (1) support early diagnosis and disease follow-up, (2) guide (stereotactic) biopsy sampling, (3) highlight the dynamic changes during disease pathogenesis in a non-invasive manner, (4) help monitor existing therapies, (5) support the development of novel TME-targeting therapies and (6) aid stratification of patients, according to the cellular composition of their tumours in correlation to their therapy response.
This chapter will summarize the most recent developments and applications of molecular imaging paradigms beyond FDG for the characterization of the dynamic molecular and cellular changes in the TME.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Change history
05 January 2021
Unfortunately the book was published with the incorrect citations in the appendix section of chapter 5. Now the citation has been updated.
References
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Inda M-D-M, Bonavia R, Seoane J (2014) Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel) 6:226–239
Villa A et al (2018) Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state. Theranostics 8:5400–5418
Derlin T, Grünwald V, Steinbach J, Wester HJ, Ross TL (2018) Molecular imaging in oncology using positron emission tomography. Dtsch Arztebl Int 115(11):175–181. https://doi.org/10.3238/arztebl.2018.0175
Di Chiro G (1987) Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors a powerful diagnostic and prognostic tool. Investig Radiol 22:360–371
Krause BJ, Schwarzenböck S, Souvatzoglou M (2013) FDG PET and PET/CT. Recent Results Cancer Res 187:351–369
Bollineni VR, Kramer GM, Jansma EP, Liu Y, Oyen WJG (2016) A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer 55:81–97
Schelhaas S et al (2017) Preclinical applications of 3′-deoxy-3′-[ 18 F]fluoro-thymidine in oncology—a systematic review. Theranostics 7:40–50
Gani Sikkandhar M et al (2017) Theranostic probes for targeting tumor microenvironment: an overview. Int J Mol Sci 18:E1036. https://doi.org/10.3390/ijms18051036
Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2012) The brain tumor microenvironment. Glia 60:502–514
Quail DF, Joyce JA (2017) The microenvironmental landscape of brain tumors. Cancer Cell 31:326–341. https://doi.org/10.1016/j.ccell.2017.02.009
Aras S, Zaidi MR (2017) TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer 117:1583–1591
Placone AL, Quiñones-Hinojosa A, Searson PC (2016) The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment. Tumor Biol 37:61–69
Ugel S, De Sanctis F, Mandruzzato S, Bronte V (2015) Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 125:3365–3376
Junck L et al (1989) PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol 26:752–758
Pappata S et al (1991) PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. J Nucl Med 32(8):1608–1610
Fookes CJR et al (2008) Synthesis and biological evaluation of substituted [18F]Imidazo[1,2-a]pyridines and [18F]Pyrazolo[1,5-a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography. J Med Chem 51:3700–3712
Imaizumi M et al (2008) Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. NeuroImage 39:1289–1298
James ML et al (2008) DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med 49:814–822
Wadsworth H et al (2012) [18F]GE-180: a novel fluorine-18 labelled PET tracer for imaging translocator protein 18kDa (TSPO). Bioorg Med Chem Lett 22:1308–1313
Winkeler A et al (2012) The translocator protein ligand [18F]DPA-714 images glioma and activated microglia in vivo. Eur J Nucl Med Mol Imaging 39:811–823
Zinnhardt B et al (2017) Combined PET imaging of the inflammatory tumor microenvironment identifies margins of unique radiotracer uptake. Cancer Res 77:1831–1841
Pigeon H et al (2019) TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma. Neuro-Oncology 21:755. https://doi.org/10.1093/neuonc/noz029
Awde AR et al (2013) The translocator protein radioligand 18F-DPA-714 monitors antitumor effect of erufosine in a rat 9L intracranial glioma model. J Nucl Med 54:2125–2131
Owen DR et al (2012) An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32:1–5
Janssen B, Vugts DJ, Windhorst AD, Mach RH (2018) PET imaging of microglial activation-beyond targeting TSPO. Molecules 23:E607
Narayanaswami V et al (2018) Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO. Mol Imaging 17:1536012118792317
Shi X, Shiao SL (2018) The role of macrophage phenotype in regulating the response to radiation therapy. Transl Res 191:64
Blykers A et al (2015) PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med 56:1265–1271
Xavier C et al (2019) Clinical translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT imaging of protumorigenic macrophages. Mol Imaging Biol 21:1–9. https://doi.org/10.1007/s11307-018-01302-5
Chockalingam S, Ghosh SS (2014) Macrophage colony-stimulating factor and cancer: a review. Tumor Biol 35:10635–10644
Horti AG et al (2019) PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci U S A 116:1686–1691
Bronte V et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150
Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5:3–8
Budhwar S, Verma P, Verma R, Rai S, Singh K (2018) The Yin and Yang of myeloid derived suppressor cells. Front Immunol 9:2776
Kumar V, Patel S, Tcyganov E, Gabrilovich DI (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37:208–220
Dubinski D et al (2016) CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol 18:807–818. https://doi.org/10.1093/neuonc/nov280
Cheng D et al (2015) Preparation and evaluation of 99m Tc-labeled anti-CD11b antibody targeting inflammatory microenvironment for colon cancer imaging. Chem Biol Drug Des 85:696–701
Cao Q, Huang Q, Mohan C, Li C (2019) μPET/CT imaging of local and systemic immune response using 64Cu-αCD11b. J Nucl Med 118:220350. https://doi.org/10.2967/jnumed.118.220350
Nigam S, McCarl L, Kumar R et al (2019) Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody. Molecular Imaging and Biology. https://doi.org/10.1007/s11307-019-01427-1
Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306
Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500
Fleming V et al (2018) Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol 9:398
Park S-M, Youn J-I (2019) Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Arch Pharm Res 42:1–7. https://doi.org/10.1007/s12272-019-01165-6
Broos K et al (2018) Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics 8:3559–3570
Heskamp S et al (2015) Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res 75:2928–2936
Josefsson A et al (2016) Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Res 76:472–479
Nedrow JR et al (2017) Imaging of programmed cell death ligand 1: impact of protein concentration on distribution of anti-PD-L1 SPECT agents in an immunocompetent murine model of melanoma. J Nucl Med 58:1560–1566
Chatterjee S et al (2016) A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 7:10215–10227
Lesniak WG et al (2016) PD-L1 detection in tumors using [(64)Cu]Atezolizumab with PET. Bioconjug Chem 27:2103–2110
Kikuchi M et al (2017) Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology 6:e1329071
Natarajan A et al (2015) Novel radiotracer for immunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytes. Bioconjug Chem 26:2062–2069
England CG et al (2017) Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled pembrolizumab. J Nucl Med 58:162–168
Cole EL et al (2017) Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates. Bioorg Med Chem 25:5407–5414
England CG et al (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110–120
Du Y et al (2017) Nuclear and fluorescent labeled PD-1-liposome-DOX-64Cu/IRDye800CW allows improved breast tumor targeted imaging and therapy. Mol Pharm 14:3978–3986
Du Y et al (2017) Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model. Int J Nanomed 12:8337–8351
Niemeijer A-LN et al (2017) Whole body PD-1 and PD-L1 PET with 89Zr-nivolumab and 18F-BMS-986192 in pts with NSCLC. J Clin Oncol 35:e20047–e20047
Higashikawa K et al (2014) 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One 9:e109866
Ehlerding EB et al (2017) ImmunoPET imaging of CTLA-4 expression in mouse models of non-small cell lung cancer. Mol Pharm 14:1782–1789
Rashidian M et al (2017) Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med 214:2243–2255
Maute RL et al (2015) Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A 112:E6506–E6514
Broos K et al (2017) Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget 8:41932–41946
Tavaré R et al (2014) Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A 111:1108–1113. https://doi.org/10.1073/pnas.1316922111
Seo JW et al (2018) CD8 + T-cell density imaging with 64Cu-labeled cys-diabody informs immunotherapy protocols. Clin Cancer Res 24:4976–4987
Tavaré R et al (2015) ImmunoPET of murine T cell reconstitution post-adoptive stem cell transplant using anti-CD4 and anti-CD8 cys-diabodies. J Nucl Med 56:1258–1264. https://doi.org/10.2967/jnumed.114.153338
Treffers LW, Hiemstra IH, Kuijpers TW, van den Berg TK, Matlung HL (2016) Neutrophils in cancer. Immunol Rev 273:312–328
Mohanty T et al (2019) Neutrophil extracellular traps in the central nervous system hinder bacterial clearance during pneumococcal meningitis. Nat Commun 10:1667. https://doi.org/10.1038/s41467-019-09040-0
Shaul ME, Fridlender ZG (2019) Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol 16:601. https://doi.org/10.1038/s41571-019-0222-4
Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ (2017) Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer 16:137. https://doi.org/10.1186/s12943-017-0707-7
Tsopelas C (2015) Radiotracers used for the scintigraphic detection of infection and inflammation. ScientificWorldJournal 2015:676719. https://doi.org/10.1155/2015/676719
Derian CK et al (1996) Selective inhibition of N-formylpeptide-induced neutrophil activation by carbamate-modified peptide analogues. Biochemistry 35:1265–1269
Locke LW et al (2009) A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-64 Cu. J Nucl Med 50:790–797. https://doi.org/10.2967/jnumed.108.056127
Pellico J et al (2017) In vivo imaging of lung inflammation with neutrophil-specific 68Ga nano-radiotracer. Sci Rep 7:13242. https://doi.org/10.1038/s41598-017-12829-y
Santi A, Kugeratski FG, Zanivan S (2018) Cancer associated fibroblasts: the architects of stroma remodeling. Proteomics 18:1–15
Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD (2014) Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl 8:454–463
Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16:582–598
Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 87:7235–7239
Levy MT et al (1999) Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 29:1768–1778
Acharya PS, Zukas A, Chandan V, Katzenstein ALA, Puré E (2006) Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol 37:352–360
Brokopp CE et al (2011) Fibroblast activation protein is induced by inflammation and degrades type i collagen in thin-cap fibroatheromata. Eur Heart J 32:2713–2722
Bauer S et al (2006) Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 8:1–11
Ariga N, Ohtani H, Nagura H, Sato E, Ohuchi N (2002) Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 95:67–72
Iwasa S, Jin X, Okada K, Mitsumata M, Ooi A (2003) Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett 199:91–98
Hofheinz RD et al (2003) Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26:44–48
Jansen K et al (2013) Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold. ACS Med Chem Lett 4:491–496
Laverman P et al (2015) Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis. J Nucl Med 56:778–783
Kratochwil C et al (2019) FAPI-PET/CT: mean intensity of tracer-uptake (SUV) in 28 different kinds of cancer. J Nucl Med 119:227967. https://doi.org/10.2967/jnumed.119.227967
Giesel FL et al (2018) 68 Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med 60:386–392
Lindner T et al (2018) Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 59:1415–1422
Loktev A et al (2018) A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med 59:1423–1429
Fischer I, Gagner J-P, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297–310
García-Figueiras R et al (2015) Imaging of tumor angiogenesis for radiologists—part 1: biological and technical basis. Curr Probl Diagn Radiol 44:407–424
Yankeelov TE, Abramson RG, Quarles CC (2014) Quantitative multimodality imaging in cancer research and therapy. Nat Rev Clin Oncol 11:670–680
Li D et al (2014) (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study. Mol Pharm 11:3923–3929
Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803
Rainer E et al (2018) The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma. Eur J Nucl Med Mol Imaging 45:2396–2403
Wenger KJ et al (2017) Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol Lett 14:1141–1146
Jansen MH et al (2017) Molecular drug imaging: 89 Zr-bevacizumab PET in children with diffuse intrinsic pontine glioma. J Nucl Med 58:711–716
Niccoli Asabella A, Di Palo A, Altini C, Ferrari C, Rubini G (2017) Multimodality imaging in tumor angiogenesis: present status and perspectives. Int J Mol Sci 18:1864
Liu J et al (2019) Design and synthesis of novel dual-cyclic RGD peptides for αvβ3 integrin targeting. Bioorg Med Chem Lett 29:896–900
Lu X, Fu Wang R (2012) A concise review of current radiopharmaceuticals in tumor angiogenesis imaging. Curr Pharm Des 18:1032–1040
Yu C et al (2015) 18 F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases. Eur J Nucl Med Mol Imaging 42:2021–2028
Zhao Z-Q, Ji S, Li X-Y, Fang W, Liu S (2019) 68Ga-labeled dimeric and trimeric cyclic RGD peptides as potential PET radiotracers for imaging gliomas. Appl Radiat Isot 148:168–177
Bekaert L et al (2017) [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging 44:1383–1392
Fushimi Y et al (2019) Grading of glioma: comparison between 18F-FMISO-PET, apparent diffusion coefficient and gadolinium enhancement. J Nucl Med 60:398–398
Kanoto M et al (2018) Correlation between hypoxic area in primary brain tumors and WHO grade: differentiation from malignancy using 18F-fluoromisonidazole positron emission tomography. Acta Radiol 59:229–235
Quartuccio N, Asselin M-C (2018) The validation path of hypoxia PET imaging: focus on brain tumours. Curr Med Chem 25:3074–3095
Häfliger P, Charles R-P (2019) The L-type amino acid transporter LAT1-an emerging target in cancer. Int J Mol Sci 20:E2428. https://doi.org/10.3390/ijms20102428
Ericson K et al (1985) Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. J Comput Assist Tomogr 9:683–689
Lundemann M et al (2019) Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma. Eur J Nucl Med Mol Imaging 46:603–613
Stegmayr C, Willuweit A, Lohmann P, Langen K-J (2019) O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) in neurooncology: a review of experimental results. Curr Radiopharm 12:201
Ikotun OF, Marquez BV, Huang C, Masuko K, Daiji M (2013) Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 ImmunoPET. PLoS One 8:77476
Cha S (2006) Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 27:475–487
Gordon Y et al (2014) Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion. Cardiovasc Diagn Ther 4:147–164
Yoo R-E, Choi SH (2016) Recent application of advanced MR imaging to predict pseudoprogression in high-grade glioma patients. Magn Reson Med Sci 15:165–177
Morabito R et al (2019) DCE and DSC perfusion MRI diagnostic accuracy in the follow-up of primary and metastatic intra-axial brain tumors treated by radiosurgery with cyberknife. Radiat Oncol 14:65
Lee SJ et al (2001) Perfusion MR imaging in gliomas: comparison with histologic tumor grade. Korean J Radiol 2:1
Gururangan S et al (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 28:3069–3075
Patel P et al (2017) MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro-Oncology 19:118–127
Barajas RF et al (2009) Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 253:486–496
Barajas RF et al (2009) Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 30:367–372. https://doi.org/10.3174/ajnr.A1362
Liu TT, Brown GG (2007) Measurement of cerebral perfusion with arterial spin labeling: part 1. Methods. J Int Neuropsychol Soc 13:517–525
Noguchi T et al (2008) Perfusion imaging of brain tumors using arterial spin-labeling: correlation with histopathologic vascular density. AJNR Am J Neuroradiol 29:688–693. https://doi.org/10.3174/ajnr.A0903
Choi YJ, Kim HS, Jahng G-H, Kim SJ, Suh DC (2013) Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging. Acta Radiol 54:448–454
Xie L et al (2019) Task-enhanced arterial spin labeled perfusion MRI predicts longitudinal neurodegeneration in mild cognitive impairment. Hippocampus 29:26–36
Nievelstein RAJ, Littooij AS (2019) Whole-body MRI in pediatric oncology. Pediatric Oncol 107–135. https://doi.org/10.1007/978-3-030-03777-2_7l
Acknowledgements
This work was partly supported by the EU seventh Framework Programme (FP7/2007–2013) under grant agreement n° 278850 (INMiND), the Horizon2020 Programme under grant agreement n° 675417 (PET3D), the “Cells-in-Motion” Cluster of Excellence (DFG EXC1003 – CiM) and the Interdisciplinary Center for Clinical Research (IZKF core unit PIX), Münster, Germany.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix
Appendix
Imaging target | Molecular target | Radiotracer | Citation |
---|---|---|---|
Tumour-associated macrophages and microglia (TAMMs) | TSPO | [11C]PK11195, [18F]PBR28, [18F]PBR111, [18F]DPA-714, [18F]GE-180 | |
CXCR1R | – | [27] | |
P2X7 and P2Y12 | [11C]A-740003, [11C]SMW139, [11C]JNJ-54173717, [11C]GSK1482160, [11C]2 | ||
M2 macrophages | [99mTc]Tc(CO)3-anti-MMR-sdAb, [18F]FB-anti-MMR-sdAbs and [68Ga]Ga-NOTA-anti-MMR-sdAb | ||
CSF-1R | [11C]CPPC | [32] | |
Myeloid-derived suppressor cells | MDSCs (CD11b+ cells) | [99mTc]-labelled anti CD11b antibody, 64Cu-antiCD11b, 89Zr anti-CD11b | |
Tumour-infiltrating lymphocytes | Cancer cell | 111In-labelled PD-L1 mAbs, atezolizumab 64Cu and 111In, 89Zr-labelled abs against PD-L1, 89Zr nivolumab and 18F-BMS-986192 | |
T cells | PD-1 antibody labelled with 64Cu, 64Cu and 89Zr pembrolizumab and nivolumab, 89Zc-Df-nivolumab, IRDye800CW- and 64Cu-labelled liposomes conjugated to PD-1 mAbs, 64Cu-labelled Mb or 89Zr-labelled cDb | ||
CTLA4 receptor | 64Cu-labelled CTLA-4 mAbs, 64Cu-labelled ipilimumab and 89Zr-labelled PEGylated single-domain antibody fragments | ||
Neutrophils | Formyl peptide receptor (FPR) | cFLFLFK-PEG-64Cu, 68Ga-NRT-cFLFLF | |
Carcinoma-associated fibroblast | Fibroblast-activating protein (FAP) | 68Ga-FAPI, 90Y-FAPI | |
Vasculature and hypoxia | VEGF receptors | [123I]-VEGF, 89Zr-labelled bevacizumab | |
αvβ3 ligand-binding domain | [18F]Alfatide II, radiolabelled RGD peptides | ||
Tumour hypoxia | [18F]FMISO | ||
LAT-1 | [11C]MET, [18F]FET, [89Zr]DFO-Ab2 |
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Foray, C. et al. (2020). Multimodal Molecular Imaging of the Tumour Microenvironment. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1225. Springer, Cham. https://doi.org/10.1007/978-3-030-35727-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-35727-6_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35726-9
Online ISBN: 978-3-030-35727-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)